579 related articles for article (PubMed ID: 22458420)
1. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia.
Schiller J; Praulich I; Krings Rocha C; Kreuzer KA
Eur J Haematol; 2012 Jul; 89(1):53-62. PubMed ID: 22458420
[TBL] [Abstract][Full Text] [Related]
2. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
[TBL] [Abstract][Full Text] [Related]
3. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
Wang YG; Liu XH; Liang Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
5. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
[TBL] [Abstract][Full Text] [Related]
6. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
7. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
8. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3.
Lin PH; Lin CC; Yang HI; Li LY; Bai LY; Chiu CF; Liao YM; Lin CY; Hsieh CY; Lin CY; Ho CM; Yang SF; Peng CT; Tsai FJ; Yeh SP
Leuk Res; 2013 Mar; 37(3):287-92. PubMed ID: 23276395
[TBL] [Abstract][Full Text] [Related]
10. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
[TBL] [Abstract][Full Text] [Related]
12. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
[TBL] [Abstract][Full Text] [Related]
13. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
14. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.
Sengsayadeth SM; Jagasia M; Engelhardt BG; Kassim A; Strickland SA; Goodman S; Lucid C; Vnencak-Jones CL; Greer JP; Savani BN
Bone Marrow Transplant; 2012 Dec; 47(12):1535-7. PubMed ID: 22659680
[TBL] [Abstract][Full Text] [Related]
15. [Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation].
Yang Z; Tian H; Xu Y; Qiu H; Chen S; Sun A; Wu D
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):94-8. PubMed ID: 24767158
[TBL] [Abstract][Full Text] [Related]
16. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
Labouré G; Dulucq S; Labopin M; Tabrizi R; Guérin E; Pigneux A; Lafarge X; Leguay T; Bouabdallah K; Dilhuydy MS; Duclos C; Lascaux A; Marit G; Mahon FX; Boiron JM; Milpied N; Vigouroux S
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1845-50. PubMed ID: 22766221
[TBL] [Abstract][Full Text] [Related]
17. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia.
Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Chang WH
Cancer; 2002 Jun; 94(12):3292-8. PubMed ID: 12115363
[TBL] [Abstract][Full Text] [Related]
19. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
20. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.
Tiesmeier J; Müller-Tidow C; Westermann A; Czwalinna A; Hoffmann M; Krauter J; Heil G; Ganser A; Serve H; Verbeek W
Leuk Res; 2004 Oct; 28(10):1069-74. PubMed ID: 15289019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
